Skip to main content
Clinical Trials/NCT05806385
NCT05806385Not yet recruitingPhase 1

Local Therapy Optimization by Grouping Immune-modulation With Cryoablation (LOGIC) for High Risk Breast Cancers

Texas Tech University Health Sciences Center0 sites36 target enrollmentStarted: March 1, 2026Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Not yet recruiting
Enrollment
36
Primary Endpoint
Rate of Complete Pathological Response

Study Overview

Brief Summary

Summary Points:

  1. High Risk Breast Cancers: Triple negative cancer is considered high risk due to high rate of local and systemic failure. Newer innovative treatment strategies are needed to improve systemic control of disease and survival.
  2. Immune system modulation: is an emerging modality in cancer treatment. Tumor antigens can stimulate T cells to identify and destroy cancer cells. Cancers express "altered self" antigens that tend to induce weaker responses than the "foreign" antigens expressed by infectious agents. Thus, immune stimulants and adjuvant approaches have been explored widely. Opportunities to develop effective cancer vaccines may benefit from seminal recent advances in understanding how immunosuppressive barricades are erected by tumors to mediate immune escape. This concept is precisely applicable to triple negative breast cancer due to their antigenicity. Checkpoint inhibitors are an attractive method for treatment of high-risk breast cancers. However, to leverage the efficacy of checkpoint inhibition, approaches are needed to enhance delivery of cancer antigens to the T cells.
  3. Cryoablation: offers an efficacious and safe method to enhance tumor antigen presentation to the immune cells while destroying the primary tumor. This ablation method is superior by virtue of antigen preservation in situ despite toxicity to the tumor cell. Impact of cryoablation in enhancing immunological responses in tumor microenvironment are well established; however, cryoablation can also cause tumor antigen tolerance via non-specific stimulation of T cells.
  4. Rationale for combining cryoablation and checkpoint inhibitors: Since checkpoint inhibitors curtail the tolerance developed by tumor antigens, and cryoablation enhances antigen presentation and T cell recruitment, it is intuitive that combination of these two approaches presents an ideal opportunity to leverage the benefits of both approaches while curtailing the limitations of either. Therefore, the investigators hypothesize in this study that their combination will improve the response rate and the degree of response.

Detailed Description

AIMS:

The main goal of proposed study is to assess synergy of tumor cryoablation and immune checkpoint inhibitor in high-risk breast cancer in humans. This will be achieved by comparing cryoablation alone and cryoablation in combination with pembrolizumab - a [checkpoint inhibitor (anti PD-1/PD-L1 antibody) currently FDA approved as cancer therapy] with the current standard of care including surgical resection. The current standard of neoadjuvant/ adjuvant therapies will remain unchanged for ethical reasons of providing best-known standard of care to all patients.

OBJECTIVES:

The investigators propose a prospective randomized exploratory trial where patients with clinical stage I/II, triple negative invasive breast cancer will be randomized to one of the three arms of the study:

  1. Standard of care - neoadjuvant therapy followed by surgical resection followed by appropriate adjuvant therapy as needed.
  2. Cryoablation arm - cryoablation followed by appropriate neoadjuvant therapy followed by surgical resection followed by appropriate adjuvant therapy as needed.
  3. Cryoablation with Pembrolizumab - Single dose of Pembrolizumab of 200 mg before (within 24-48 hours) of cryoablation followed by appropriate neoadjuvant therapy followed by surgical resection followed by appropriate adjuvant therapy as needed.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

Since proposed intervention ( cryoablation and immune therapy infusion) cannot be masked with placebo, only the data analyst will be masked.

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Stage I/II Cancer
  • Age range 18 - 90 years
  • Diagnoses: Invasive carcinoma, ER -, PR-, HER2- (triple negative)
  • Radiology findings: Unifocal disease visible on ultrasound

Exclusion Criteria

  • Additional primary cancer
  • Inflammatory breast cancer
  • History of autoimmune disease
  • History of chronic immunosuppression
  • Prior immunotherapy
  • Recent vaccination (within 4 wks.)
  • Prior radiation therapy
  • Prior investigational agent therapy within last 1 year
  • Pregnancy at the time of diagnosis and/ or treatment
  • Breast feeding

Outcomes

Primary Outcomes

Rate of Complete Pathological Response

Time Frame: 6-8 months

Pathological analysis of tumor after completion of local and neoadjuvant therapy

Secondary Outcomes

  • Percent change is Tumor Infiltrating Lymphocytes Score(6-8 month)
  • Percent change is Tumor Infiltrating Lymphocytes Score(6-8 month)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Rakhshanda Rahman

Professor Surgical Oncology

Texas Tech University Health Sciences Center

Similar Trials